---
title: CDMO Services for Polymers & LNPs | GMP Manufacturing & Fill-Finish
description: "Curapath is a CDMO for lipid & polymer-based drug delivery: GMP manufacturing, formulation development, analytics, and aseptic fill-finish."
image: https://resources.curapath.com/hubfs/Def%20Curapath%20CDMO-3.pdf.jpg
---

[![White](https://resources.curapath.com/hs-fs/hubfs/White.png?width=1063&height=400&name=White.png "White")](https://curapath.com/)

 Resources

# CDMO Services for Advanced Drug Delivery (LNPs, PNPs & Next-Gen Polymers)

[Back to resources](https://resources.curapath.com/en/curapath-resource-library?hsCtaTracking=fca93105-47df-4ecb-8060-ab8c884fed09%7C49317d58-fe6c-4c70-83cc-d920d6200f8d&hsLang=en)

## From early formulation development to GMP manufacturing and aseptic Fill & Finish, supporting innovative therapeutics from preclinical to commercial supply.

# Explore Our Complete CDMO Capabilities

Explore our CDMO Services overview, outlining our integrated approach to advanced lipid and polymer-based drug delivery, from early development to GMP manufacturing and aseptic Fill & Finish.

**Download now to discover how Curapath supports complex delivery platforms through formulation expertise, scalable manufacturing, and regulatory-aligned infrastructure.**

![Def Curapath CDMO-3.pdf](https://resources.curapath.com/hs-fs/hubfs/Def%20Curapath%20CDMO-3.pdf.jpg?width=1414&height=2000&name=Def%20Curapath%20CDMO-3.pdf.jpg)

The CDMO Services leaflet provides a detailed overview of:

- **Manufacturing infrastructure**
- **Analytical expertise**
- **Scale-up strategy**
- **Fill & Finish operations**
- **Development-to-GMP transition model**

 

## A Specialized CDMO for Complex Delivery Platforms

Curapath supports biotechnology and pharmaceutical companies developing next-generation therapeutics using lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and precision polymer systems.

Our integrated approach bridges formulation science, process development, GMP manufacturing, and analytical control ,  enabling efficient scale-up and regulatory alignment.

 

## From Development to GMP Manufacturing

We support programs across:

- Novel excipients and advanced carrier systems
- Lipid- and polymer-based **drug substance (DS) development and GMP manufacturing**
- Nanoparticle **drug product (DP) formulation and scale-up**
- Integrated **analytical development, method validation, and quality control**
- Sterile Fill & Finish operations for advanced therapeutics

Each project is structured to ensure scalability, reproducibility, regulatory alignment, and seamless transition from development to GMP production.

 

## Built for Complex Modalities

**Our CDMO services are designed for advanced therapeutics including:**

- RNA-based medicines (mRNA, siRNA and other nucleic acid modalities)
- Cell & gene therapies
- Polymer–drug conjugates and precision polymer systems
- Lipid nanoparticles (LNPs) and polymer nanoparticle (PNP) platforms
- Targeted and non-viral delivery systems for complex biologics

We support innovative programs requiring specialized carrier technologies, scalable manufacturing strategies, and regulatory-aligned development pathways.

 Targeted LNP Shielding Lipids

## Frequently asked Questions

##### [About Curapath What is Curapath?](https://resources.curapath.com/cdmo-services-brochure#collapse1-module_17715838631525)

[Curapath](https://curapath.com/about-us/)is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing.

Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers.

##### [CDMO Services What CDMO services does Curapath provide?](https://resources.curapath.com/cdmo-services-brochure#collapse2-module_17715838631525)

 Curapath provides integrated CDMO services covering drug substance (DS) and drug product (DP) development, GMP manufacturing of lipids and polymers, nanoparticle formulation, analytical development, quality control, and aseptic Fill & Finish operations. 

More abour our[end-to-end services](https://curapath.com/end-to-end-services/)

##### [CDMO Services Do you work with cell and gene therapy programs?](https://resources.curapath.com/cdmo-services-brochure#collapse3-module_17715838631525)

Yes. We support advanced therapeutic modalities including RNA-based medicines, cell and gene therapies, and non-viral delivery platforms requiring specialized carrier systems and GMP-aligned manufacturing.

Our experience includes support for programs such as in vivo gene editing approaches, RNA therapeutics, and emerging strategies like [in vivo CAR-T](https://blog.curapath.com/reimagining-car-t-therapy-in-vivo-engineering-with-lipid-nanoparticles?hsLang=en) platforms enabled by lipid nanoparticle (LNP) delivery. We also develop [PEG-alternative](https://blog.curapath.com/peg-alternatives?hsLang=en)shielding systems, including polysarcosine-based lipids and polymers, designed to improve safety profile and enable repeat dosing strategies.

Each program is supported through integrated drug substance, drug product, and analytical development workflows to ensure scalability and regulatory readiness.

 

##### [CDMO Services Do you offer analytical development and QC services?](https://resources.curapath.com/cdmo-services-brochure#collapse4-module_17715838631525)

 Yes. Our integrated analytical services include method development, validation, stability studies, and quality control testing to support regulatory submissions and GMP manufacturing. 

Quality development aligned qwith each market regulatory requirements:

- Controlled rooms for **medical-device ingredients**
- ICH Q11-guided **excipient development**
- GMP / ICH Q7-aligned **drug-substance** manufacturing

##### [CDMO Services Do you provide aseptic Fill & Finish?](https://resources.curapath.com/cdmo-services-brochure#collapse5-module_17715838631525)

Yes. We offer aseptic Fill & Finish operations for advanced therapeutics, supporting clinical-stage programs and regulatory-aligned production requirements.

Our capabilities include multiple sterile formats such as glass vials (various fill volumes and configurations), bottles, prefilled syringes, and flexible bags. We support both liquid and lyophilized presentations depending on product requirements.

Fill & Finish operations are performed within controlled cleanroom environments, with integrated environmental monitoring, sterility assurance, and Qualified Person (QP) release processes to ensure compliance with GMP standards.

 

##### [CDMO Services How can I discuss a project with the team?](https://resources.curapath.com/cdmo-services-brochure#collapse6-module_17715838631525)

 You can initiate a discussion by contacting our team  After reviewing your modality, development stage, and target specifications, we will propose a tailored technical and manufacturing pathway. 

We will be happy to discuss your needs and how we can help you, you can send the details [here](https://curapath.com/contact-us/)

[Contact](https://curapath.com/contact-us/)

## Resources

### [CDMO Brochure Optimize Your Formulation Processes and Fill & Finish Requests with Robust Precision Lipid and Polymer Services](https://resources.curapath.com/en/curapath-cdmo-brochure-download?hsLang=en)

### [pSar White Paper Polysarcosine (pSar), a safer, more effective alternative to poly-ethylene glycol (PEG)](https://resources.curapath.com/en/curapath-psar-white-paper-download?hsLang=en)

<https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en>

### [Next generation LNPs formulation with Certest’s and Curapath’s proprietary excipients](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en)

[<https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en>](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en)

Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients

 

### [Polymeric Nanoparticles Case Study Development of a Highly Efficient, Biodegradable, Polymeric, Non-viral Vector (NVV) Platform for Nucleic Acid Delivery](https://resources.curapath.com/en/curapath-pol-nano-case-study?hsLang=en)

### [Curapath-Knauer Application Note Development and Optimization of LNP Formulations using the NanoScaler](https://resources.curapath.com/en/curapath-knauer-app-note?hsLang=en)

### [pSar-VitE General Excipient Case Study Development of PEG-free Excipients for Drug Delivery](https://resources.curapath.com/en/vite-psar-general-excipient?hsLang=en)

### [Curapath-Knauer Services Flyer LNP Formulation and Analytical Services](https://resources.curapath.com/en/curapath-knauer-flyer-download?hsLang=en)

![Lipid-Nanopeptide\_0](https://resources.curapath.com/hs-fs/hubfs/Lipid-Nanopeptide_0.png?width=500&height=500&name=Lipid-Nanopeptide_0.png)

 Support for Your Therapeutic Program

### Contact a Chemist Today

Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug.

[Contact Us](https://curapath.com/?page_id=151)

![footer-Logo](https://resources.curapath.com/hubfs/footer-Logo.svg "footer-Logo")

[End-to-End Services](https://curapathstg.wpenginepowered.com/end-to-end-services/)

[Expertise](https://curapathstg.wpenginepowered.com/expertise/)

[Non-Viral Gene Delivery](https://curapathstg.wpenginepowered.com/non-viral-gene-delivery/)

[Polymer & Lipid Excipients](https://curapathstg.wpenginepowered.com/polymer-lipid-excipients/)

[Analytics & Metrics](https://curapathstg.wpenginepowered.com/analytics-and-metrics/)

[Products](https://20205171.hs-sites.com/en/curapath-product-catalog?hsLang=en)

[Resources](https://20205171.hs-sites.com/en/curapath-resource-library?hsCtaTracking=fca93105-47df-4ecb-8060-ab8c884fed09%7C49317d58-fe6c-4c70-83cc-d920d6200f8d&hsLang=en)

[About Us](https://curapath.com/about-us/)

[Contact](https://curapath.com/contact-us/)

[Testimonials](https://curapath.com/testimonials/)

[News & Events](https://curapath.com/news-events/)

[Careers](https://curapath.com/careers/)

[Privacy](https://curapath.com/privacy-policy/)

[Cookie Policy](https://curapath.com/cookies-policy/)

[Legal Notice](https://curapath.com/legal-notice/)

US Commercial Offices

One Broadway, 14th Floor  
Cambridge, MA 02142  
USA

GMP Production Site & Headquarters

Av. Benjamin Franklin 19  
46980 Paterna, Valencia  
Spain

Innovation & Development Site

C/Alexander Graham Bell 6 46980 Paterna, Valencia Spain

[![In-White-96@2x-1](https://resources.curapath.com/hs-fs/hubfs/In-White-96@2x-1.png?width=30&height=30&name=In-White-96@2x-1.png "In-White-96@2x-1")](https://www.linkedin.com/company/curapath/)

Copyright © 2024 Curapath. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "Service",
  "areaServed" : {
    "@type" : "Place",
    "name" : "Global"
  },
  "description" : "Integrated CDMO services covering drug substance and drug product development, GMP manufacturing of lipids and polymers, nanoparticle formulation, analytical development, and aseptic Fill & Finish for advanced therapeutics.",
  "name" : "CDMO Services for Lipid and Polymer-Based Drug Delivery",
  "provider" : {
    "@type" : "Organization",
    "name" : "Curapath",
    "url" : "https://curapath.com"
  },
  "serviceType" : [ "GMP Manufacturing", "Drug Substance Development", "Drug Product Development", "LNP Manufacturing", "Polymer Manufacturing", "Analytical Development", "Aseptic Fill & Finish" ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing. Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers."
    },
    "name" : "What is Curapath?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Curapath provides integrated CDMO services covering drug substance (DS) and drug product (DP) development, GMP manufacturing of lipids and polymers, nanoparticle formulation, analytical development, quality control, and aseptic Fill & Finish operations."
    },
    "name" : "What CDMO services does Curapath provide?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. We support advanced therapeutic modalities including RNA-based medicines, cell and gene therapies, and non-viral delivery platforms requiring specialized carrier systems and GMP-aligned manufacturing. Our experience includes support for programs such as in vivo gene editing approaches, RNA therapeutics, and emerging strategies like in vivo CAR-T platforms enabled by lipid nanoparticle (LNP) delivery. We also develop PEG-alternative shielding systems, including polysarcosine-based lipids and polymers, designed to improve safety profile and enable repeat dosing strategies. Each program is supported through integrated drug substance, drug product, and analytical development workflows to ensure scalability and regulatory readiness."
    },
    "name" : "Do you work with cell and gene therapy programs?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. Our integrated analytical services include method development, validation, stability studies, and quality control testing to support regulatory submissions and GMP manufacturing. Quality development is aligned with each market’s regulatory requirements."
    },
    "name" : "Do you offer analytical development and quality control services?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. We offer aseptic Fill & Finish operations for advanced therapeutics, supporting clinical-stage programs and regulatory-aligned production requirements. Our capabilities include multiple sterile formats such as glass vials (various fill volumes and configurations), bottles, prefilled syringes, and flexible bags. We support both liquid and lyophilized presentations depending on product requirements. Fill & Finish operations are performed within controlled cleanroom environments, with integrated environmental monitoring, sterility assurance, and Qualified Person (QP) release processes to ensure compliance with GMP standards."
    },
    "name" : "Do you provide aseptic Fill & Finish?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. We support controlled-room manufacturing for medical-device ingredients, ICH Q11-guided excipient development, and GMP / ICH Q7-aligned drug-substance manufacturing depending on project scope and requirements."
    },
    "name" : "Do you offer GMP-aligned development for excipients and drug substances?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "You can initiate a discussion by contacting our team through the form on this page. After reviewing your modality, development stage, and target specifications, we will propose a tailored technical and manufacturing pathway. We will be happy to discuss your needs and how we can help you."
    },
    "name" : "How can I start a project with Curapath?"
  } ]
}
```